Decitabine Plus mBU/CY for High Risk Acute Leukemia With MRD Pre-HSCT

Launched by PEKING UNIVERSITY PEOPLE'S HOSPITAL · Jan 3, 2019

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment approach for patients with high-risk acute leukemia who still have detectable cancer cells before undergoing a stem cell transplant. The goal is to see if combining a drug called decitabine with modified doses of busulfan and cyclophosphamide (two other medications) can improve outcomes for these patients and reduce the chances of leukemia coming back after the transplant.

To be eligible for this trial, participants need to be adults aged between 65 and 74 years who have specific types of acute leukemia and still show signs of the disease before the transplant. Pregnant women and those with severe infections that are not under control cannot participate. If you join the trial, you will receive the combination treatment and be monitored closely to see how well it works. This trial is currently recruiting participants, so it could be a valuable opportunity for those facing challenges with their leukemia treatment.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • acute leukemia patients with MLL-r,TLS-ERG,or SIL-TAL1,whose minimal residual disease were detectable pre-HSCT
• Exclusion Criteria:
• • pregnancy women
• • uncontrolled severe infection